Adenine Base Editing of APOE4 to APOE3 for Alzheimer's Prevention

Migration, Crosslink

📖

Adenine Base Editing of APOE4 to APOE3 for Alzheimer's Prevention

active

wiki page Created: 2026-04-02T07:19:34 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-payload-base-editing-apoe4

📖 Wiki Page

idea705 wordssynced 2026-04-02

Base Editing for APOE4

Additional evidence sources:

Overview

Pathway / Mechanism Diagram

graph TD A["APOE Gene"] --> B["APOE e2 (Protective)"] A --> C["APOE e3 (Neutral)"] A --> D["APOE e4 (Risk Factor)"] D --> E["Impaired Abeta Clearance"] D --> F["Enhanced Tau Phosphorylation"] D --> G["BBB Dysfunction"] D --> H["Reduced Lipid Transport"] E --> I["Amyloid Accumulation"] F --> J["Tangle Formation"] G --> K["Neuroinflammation"] H --> L["Impaired Synaptic Repair"] I --> M["Neurodegeneration"] J --> M K --> M L --> M B --> N["Enhanced Abeta Clearance"] N --> O["Reduced AD Risk"] style D fill:#ef5350,color:#e0e0e0 style B fill:#1b5e20,color:#e0e0e0 style M fill:#ef5350,color:#e0e0e0

Cross-Links

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[APOE4 Homozygous Risk](/diseases/apoe4-risk)

Genes & Proteins

[APOE](/genes/apoe)
[APOE4](/diseases/apoe4)
[Amyloid Precursor Protein](/proteins/app)

Mechanisms

[Amyloid Clearance](/mechanisms/amyloid-clearance)
[Lipid Metabolism](/mechanisms/lipid-metabolism)mechanisms/sphingolipid-metabolism)
[Synaptic Function](/mechanisms/synaptic-function)
[Neuroinflammation](/mechanisms/neuroinflammation)

Cell Types

[Astrocytes](/cell-types/astrocytes)
[Microglia](/cell-types/microglia)
[Neurons](/cell-types/neurons)

...

Base Editing for APOE4

Additional evidence sources:

Overview

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Cross-Links

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[APOE4 Homozygous Risk](/diseases/apoe4-risk)

Genes & Proteins

[APOE](/genes/apoe)
[APOE4](/diseases/apoe4)
[Amyloid Precursor Protein](/proteins/app)

Mechanisms

[Amyloid Clearance](/mechanisms/amyloid-clearance)
[Lipid Metabolism](/mechanisms/lipid-metabolism)mechanisms/sphingolipid-metabolism)
[Synaptic Function](/mechanisms/synaptic-function)
[Neuroinflammation](/mechanisms/neuroinflammation)

Cell Types

[Astrocytes](/cell-types/astrocytes)
[Microglia](/cell-types/microglia)
[Neurons](/cell-types/neurons)

[Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
[APOE4 Modulation](/therapeutics/apoe4-modulation)
[Base Editing](/therapeutics/base-editing-therapy)

Biomarkers

[CSF APOE](/biomarkers/csf-apoe)
[Amyloid PET](/biomarkers/amyloid-pet)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment (MCI)](/diseases/mild-cognitive-impairment)
[Parkinson's Disease](/diseases/parkinsons-disease)

Genes & Proteins

[APOE](/genes/apoe)
[APOE4](/diseases/apoe4)
[APOE3](/diseases/apoe3)
[Tau](/proteins/tau)
[Amyloid Beta](/proteins/amyloid-beta)
[LRP1](/proteins/lrp1)
[TREM2](/proteins/trem2-protein)

Mechanisms

[Amyloid Cascade](/mechanisms/amyloid-cascade)
[Tau Pathology](/mechanisms/tau-pathology)
[Blood-Brain Barrier](/cell-types/blood-brain-barrier)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Lipid Metabolism](/mechanisms/lipid-metabolism-neurodegeneration)
ApoE Lipidation

Cell Types

[Astrocytes](/cell-types/astrocytes)
[Neurons](/cell-types/neurons)
[Microglia](/cell-types/microglia)
[Pericytes](/cell-types/pericytes)

Treatments

[Gene Therapy](/technologies/gene-therapy)
[Base Editing](/technologies/base-editing)
AAV Delivery
CRISPR Therapy
[Immunotherapy](/therapeutics/immunotherapy)

[LRP1-Targeted ApoE Peptide Delivery](/proteins/lrp1)
TREM2 Microglia Modulation
[BBB Transcytosis PROTAC](/ideas/bbb-transcytosis-protac)

Diseases

[Alzheimer's Disease — Primary target indication](/diseases/alzheimers-disease)
[Parkinson's Disease — Secondary target](/diseases/parkinsons-disease)
[Mild Cognitive Impairment — Early intervention](/diseases/mild-cognitive-impairment)

Genes

[APOE — Target gene for base editing](/genes/apoe)
[APOE4 — Risk allele being converted](/diseases/apoe4)
[PSEN1 — AD risk modifier](/genes/psen1)

Proteins

[Tau Protein — Downstream pathology](/proteins/tau)
[Amyloid Beta — AD hallmark pathology](/proteins/amyloid-beta)
[LRP1 — APOE receptor, BBB transport](/proteins/lrp1)

Mechanisms

[Amyloid Cascade Hypothesis — Disease mechanism](/mechanisms/amyloid-cascade-hypothesis)
[Tau Pathology — Downstream degeneration](/mechanisms/tau-pathology)
Blood-Brain Barrier — Delivery challenge
[Neuroinflammation — Disease mechanism](/mechanisms/neuroinflammation)
Lipid Metabolism in Brain — APOE function

Cell Types

[Astrocytes — Brain lipid homeostasis](/cell-types/astrocytes)
[Neurons — Target cells](/cell-types/neurons)
[Microglia — Immune modulation](/cell-types/microglia)

Treatments

Gene Therapy for Neurodegeneration — Therapeutic approach
Base Editing Therapy — Therapeutic modality
AAV Delivery Methods — Vector choice

Actionable Next Steps

Preclinical Validation: Test base editing efficiency in APOE4 knock-in neuronal models

Delivery Optimization: Compare AAV versus lipid nanoparticle delivery for brain penetration

Safety Assessment: Evaluate off-target editing and immune responses in relevant models

Implementation Roadmap

Phase 1 (0-6 months): In vitro validation of base editing constructs in cell models
Phase 2 (6-18 months): Preclinical efficacy and toxicity studies in animal models
Phase 3 (18-36 months): IND-enabling studies and regulatory consultations

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov/) — Search for relevant clinical trials
[Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
[Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research and resources
[NIH National Institute on Aging](https://www.nia.nih.gov/) — Funding and research resources

References

[Gaudelli NM, Komor AC, Rees HA, et al, Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage (2017)](https://pubmed.ncbi.nlm.nih.gov/29160308/))

[Rees HA, Liu DR, Base editing: precision chemistry on the genome and transcriptome of living cells (2018)](https://pubmed.ncbi.nlm.nih.gov/30442934/))

[Yamazaki Y, Zhao N, Caulfield TR, et al, Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies (2019)](https://pubmed.ncbi.nlm.nih.gov/31367008/))

[Corder EH, Saunders AM, Strittmatter WJ, et al, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families (1993)](https://pubmed.ncbi.nlm.nih.gov/8346443/))

[Shi Y, Yamada K, Liddelow SA, et al, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy (2017)](https://pubmed.ncbi.nlm.nih.gov/28966368/))

[Arboleda-Velasquez JF, Lopera F, O'Hare M, et al, Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report (2019)](https://pubmed.ncbi.nlm.nih.gov/31672369/))

[Barthélemy NR, Horie K, Sato C, Bhatt DK, Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32123386/))

[Musunuru K, Chadwick AC, Mizoguchi T, et al, In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates (2021)](https://pubmed.ncbi.nlm.nih.gov/33992038/))

[Levy JM, Yeh WH, Pendse N, et al, Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses (2020)](https://pubmed.ncbi.nlm.nih.gov/32895555/))

[Belloy ME, Napolioni V, Greicius MD, A quarter century of APOE and Alzheimer's disease: progress to date and the path forward (2019)](https://pubmed.ncbi.nlm.nih.gov/31727856/))

[Serrano-Pozo A, Das S, Bhatt DK, APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches (2021)](https://pubmed.ncbi.nlm.nih.gov/33986542/))

📖 View canonical wiki page →

Related Entities

ideas-payload-base-editing-apoe4

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-payload-base-editing-apoe4
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-45a848178acf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-payload-base-editing-apoe4'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

230

Outgoing

247

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Adenine Base Editing of APOE4 to APOE3 for Alzheimer's Prevention

Base Editing for APOE4

Overview

Pathway / Mechanism Diagram

Cross-Links

Diseases

Genes & Proteins

Mechanisms

Cell Types

Base Editing for APOE4

Overview

Pathway / Mechanism Diagram

Cross-Links

Diseases

Genes & Proteins

Mechanisms

Cell Types

Biomarkers

Diseases

Genes & Proteins

Mechanisms

Cell Types

Treatments

Diseases

Genes

Proteins

Mechanisms

Cell Types

Treatments

Actionable Next Steps

Implementation Roadmap

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Adenine Base Editing of APOE4 to APOE3 for Alzheimer's Prevention

Base Editing for APOE4

Overview

Pathway / Mechanism Diagram

Cross-Links

Diseases

Genes & Proteins

Mechanisms

Cell Types

Base Editing for APOE4

Overview

Pathway / Mechanism Diagram

Cross-Links

Diseases

Genes & Proteins

Mechanisms

Cell Types

Related Therapies

Biomarkers

Cross-Links to Related Pages

Diseases

Genes & Proteins

Mechanisms

Cell Types

Treatments

Related Therapy Ideas

Diseases

Genes

Proteins

Mechanisms

Cell Types

Treatments

Actionable Next Steps

Implementation Roadmap

See Also

External Links

References

💬 Discussion